<DOC>
	<DOCNO>NCT01883167</DOCNO>
	<brief_summary>This study evaluate potential pharmacokinetic ( PK ) pharmacodynamic ( PD ) interaction XO inhibitor febuxostat investigational URAT1 inhibitor RDEA3170 provide information potential future clinical study use combination . Combination treatment use 2 drug different mechanism action may achieve improve response may allow use low dos , result few side effect use either drug alone .</brief_summary>
	<brief_title>RDEA3170 Febuxostat Drug Interaction Study</brief_title>
	<detailed_description />
	<mesh_term>Febuxostat</mesh_term>
	<criteria>body weight ≥ 50 kg ( 110 lb . ) body mass index ≥ 18 ≤ 40 kg/m2 . clinically relevant abnormality vital sign , ECG , physical examination safety laboratory value , per Investigator 's judgment . screen serum urate level ≥ 4.5 mg/dL . history suspicion kidney stone . history cardiac abnormality assess screening , include abnormal clinically relevant electrocardiogram change and/or family history sudden death otherwise healthy individual age 1 30 year . undergone major surgery within 3 month prior Day 1. donate blood experienced significant blood loss ( &gt; 450 mL ) within 12 week prior Day 1 give plasma donation within 4 week prior Screening Period . inadequate venous access unsuitable vein repeat venipuncture .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>